Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma

Authors: Li-Ming Wu, Zhe Yang, Lin Zhou, Feng Zhang, Hai-Yang Xie, Xiao-Wen Feng, Jian Wu, Shu-Sen Zheng

DOI: 10.1371/journal.pone.0014460

Abstract Summary

HDAC3, a histone-modifying enzyme, emerges as a key player in hepatocellular carcinoma progression. High HDAC3 expression predicts poor recurrence-free survival in liver transplant patients and independently forecasts outcomes. Inhibiting HDAC3 suppresses cancer cell growth and invasion, suggesting it could serve as both a prognostic biomarker and therapeutic target for HCC.

Why Brain? 🧠

HDAC3 protein predicts hepatocellular carcinoma recurrence after liver transplant in hepatitis B patients and may serve as a therapeutic target to reduce tumor spread and improve outcomes.

The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.